StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)

Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –

Regeneron Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Regeneron Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was $3.83B, down 9.4% year over year. For fiscal 2025 it was $4.08B, up 11.3% from the year before. Over ten years it grew 20.1% a year on average. The highest annual figure on record is $6.53B in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.08B+11.3%
FY2024Dec 31, 2024$3.66B-5.4%
FY2023Dec 31, 2023$3.88B-12.4%
FY2022Dec 31, 2022$4.42B-32.2%
FY2021Dec 31, 2021$6.53B+225.9%
FY2020Dec 31, 2020$2.00B+0.2%
FY2019Dec 31, 2019$2.00B+10.4%
FY2018Dec 31, 2018$1.81B+75.2%
FY2017Dec 31, 2017$1.03B+6.2%
FY2016Dec 31, 2016$974.00M+49.2%
FY2015Dec 31, 2015$652.85M+55.7%
FY2014Dec 31, 2014$419.43M-3.0%
FY2013Dec 31, 2013$432.27M–
FY2012Dec 31, 2012-$123.95M–
FY2011Dec 31, 2011-$198.90M–
FY2010Dec 31, 2010-$467.00K–
FY2009Dec 31, 2009-$167.25M–
FY2008Dec 31, 2008-$123.94M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.48B+4.6%
Q2 FY2026Jun 30, 2026$572.80M-38.1%
Q1 FY2026Mar 31, 2026$848.30M+4.0%
Q4 FY2025Dec 31, 2025$922.00M-13.3%
Q3 FY2025Sep 30, 2025$1.42B+35.1%
Q2 FY2025Jun 30, 2025$925.40M+433.4%
Q1 FY2025Mar 31, 2025$815.80M-40.8%
Q4 FY2024Dec 31, 2024$1.06B+26.8%
Q3 FY2024Sep 30, 2024$1.05B+11.8%
Q2 FY2024Jun 30, 2024$173.50M-80.9%
Q1 FY2024Mar 31, 2024$1.38B+15.9%
Q4 FY2023Dec 31, 2023$838.30M-46.5%
Q3 FY2023Sep 30, 2023$938.30M+92.9%
Q2 FY2023Jun 30, 2023$909.40M+121.4%
Q1 FY2023Mar 31, 2023$1.19B-39.3%
Q4 FY2022Dec 31, 2022$1.57B-29.3%
Q3 FY2022Sep 30, 2022$486.40M-85.2%
Q2 FY2022Jun 30, 2022$410.80M-14.1%
Q1 FY2022Mar 31, 2022$1.96B+254.3%
Q4 FY2021Dec 31, 2021$2.22B+107.3%
Q3 FY2021Sep 30, 2021$3.28B–
Q2 FY2021Jun 30, 2021$478.20M-41.2%
Q1 FY2021Mar 31, 2021$553.20M+4.8%
Q4 FY2020Dec 31, 2020$1.07B+65.0%
Q3 FY2020Sep 30, 2020-$407.50M-193.5%
Q2 FY2020Jun 30, 2020$813.50M+768.2%
Q1 FY2020Mar 31, 2020$527.90M-35.8%
Q4 FY2019Dec 31, 2019$648.40M+0.8%
Q3 FY2019Sep 30, 2019$435.60M+25.6%
Q2 FY2019Jun 30, 2019$93.70M-66.8%
Q1 FY2019Mar 31, 2019$822.70M+52.5%
Q4 FY2018Dec 31, 2018$643.30M+40.1%
Q3 FY2018Sep 30, 2018$346.70M-2.4%
Q2 FY2018Jun 30, 2018$282.60M–
Q1 FY2018Mar 31, 2018$539.40M+76.6%
Q4 FY2017Dec 31, 2017$459.30M+91.4%
Q3 FY2017Sep 30, 2017$355.18M–
Q2 FY2017Jun 30, 2017-$85.42M–
Q1 FY2017Mar 31, 2017$305.44M–
Q4 FY2016Dec 31, 2016$239.97M–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?